Susquehanna International Group’s Protalix BioTherapeutics PLX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $383K | Buy |
+176,600
| New | +$438K | ﹤0.01% | 10320 |
|
|
2025
Q4 | – | Sell |
-23,600
| Closed | -$52.4K | – | 13307 |
|
|
2025
Q3 | $52.4K | Sell |
23,600
-144,300
| -86% | -$235K | ﹤0.01% | 11845 |
|
|
2025
Q2 | $248K | Sell |
167,900
-8,500
| -5% | -$17.4K | ﹤0.01% | 10755 |
|
|
2025
Q1 | $452K | Buy |
+176,400
| New | +$421K | ﹤0.01% | 9120 |
|
|
2024
Q3 | – | Sell |
-17,400
| Closed | -$20.4K | – | 12785 |
|
|
2024
Q2 | $20.4K | Sell |
17,400
-10,400
| -37% | -$12.3K | ﹤0.01% | 11663 |
|
|
2024
Q1 | $35K | Sell |
27,800
-45,200
| -62% | -$67.5K | ﹤0.01% | 11666 |
|
|
2023
Q4 | $130K | Sell |
73,000
-56,000
| -43% | -$87.1K | ﹤0.01% | 11108 |
|
|
2023
Q3 | $214K | Sell |
129,000
-266,300
| -67% | -$478K | ﹤0.01% | 10085 |
|
|
2023
Q2 | $791K | Sell |
395,300
-60,500
| -13% | -$144K | ﹤0.01% | 7225 |
|
|
2023
Q1 | $957K | Buy |
455,800
+101,700
| +29% | +$178K | ﹤0.01% | 6936 |
|
|
2022
Q4 | $485K | Buy |
354,100
+104,700
| +42% | +$115K | ﹤0.01% | 7940 |
|
|
2022
Q3 | $259K | Sell |
249,400
-131,800
| -35% | -$146K | ﹤0.01% | 10178 |
|
|
2022
Q2 | $416K | Buy |
381,200
+124,400
| +48% | +$146K | ﹤0.01% | 8729 |
|
|
2022
Q1 | $272K | Buy |
256,800
+219,900
| +596% | +$201K | ﹤0.01% | 10502 |
|
|
2021
Q4 | $31K | Sell |
36,900
-202,400
| -85% | -$212K | ﹤0.01% | 12734 |
|
|
2021
Q3 | $318K | Sell |
239,300
-274,700
| -53% | -$417K | ﹤0.01% | 10473 |
|
|
2021
Q2 | $982K | Buy |
514,000
+441,200
| +606% | +$1.52M | ﹤0.01% | 7815 |
|
|
2021
Q1 | $325K | Buy |
72,800
+48,000
| +194% | +$223K | ﹤0.01% | 10437 |
|
|
2020
Q4 | $90K | Sell |
24,800
-5,400
| -18% | -$19.4K | ﹤0.01% | 10548 |
|
|
2020
Q3 | $117K | Sell |
30,200
-135,700
| -82% | -$491K | ﹤0.01% | 9826 |
|
|
2020
Q2 | $629K | Buy |
165,900
+139,700
| +533% | +$478K | ﹤0.01% | 6870 |
|
|
2020
Q1 | $62K | Buy |
+26,200
| New | +$86.6K | ﹤0.01% | 9577 |
|
|
2019
Q4 | – | Sell |
-7,950
| Closed | -$16K | – | 10414 |
|
|
2019
Q3 | $16K | Sell |
7,950
-60
| -0.7% | -$179 | ﹤0.01% | 9972 |
|
|
2019
Q2 | $38K | Buy |
8,010
+6,610
| +472% | +$27.9K | ﹤0.01% | 9898 |
|
|
2019
Q1 | $6K | Sell |
1,400
-1,440
| -51% | -$6.49K | ﹤0.01% | 8672 |
|
|
2018
Q4 | $9K | Buy |
+2,840
| New | +$13.5K | ﹤0.01% | 8753 |
|
|
2017
Q4 | – | Sell |
-19,250
| Closed | -$112K | – | 9758 |
|
|
2017
Q3 | $112K | Buy |
19,250
+5,340
| +38% | +$34.2K | ﹤0.01% | 8320 |
|
|
2017
Q2 | $116K | Buy |
13,910
+8,620
| +163% | +$80.9K | ﹤0.01% | 8619 |
|
|
2017
Q1 | $72K | Buy |
+5,290
| New | +$47.6K | ﹤0.01% | 8503 |
|
|
2016
Q1 | – | Sell |
-3,880
| Closed | -$40K | – | 9503 |
|
|
2015
Q4 | $40K | Buy |
3,880
+2,290
| +144% | +$23.3K | ﹤0.01% | 9143 |
|
|
2015
Q3 | $19K | Sell |
1,590
-1,420
| -47% | -$22.6K | ﹤0.01% | 9507 |
|
|
2015
Q2 | $59K | Buy |
+3,010
| New | +$62.4K | ﹤0.01% | 9840 |
|
|
2014
Q4 | – | Sell |
-3,290
| Closed | -$80K | – | 9979 |
|
|
2014
Q3 | $80K | Sell |
3,290
-5,290
| -62% | -$152K | ﹤0.01% | 9131 |
|
|
2014
Q2 | $313K | Buy |
8,580
+5,490
| +178% | +$221K | ﹤0.01% | 8307 |
|
|
2014
Q1 | $142K | Buy |
+3,090
| New | +$144K | ﹤0.01% | 8443 |
|
|
2013
Q4 | – | Sell |
-3,190
| Closed | -$145K | – | 9232 |
|
|
2013
Q3 | $145K | Sell |
3,190
-7,470
| -70% | -$383K | ﹤0.01% | 7930 |
|
|
2013
Q2 | $523K | Buy |
+10,660
| New | +$566K | ﹤0.01% | 5971 |
|
Other funds holding PLX
MCO
SWP
VPM
PFS
OM
Susquehanna International Group's PLX Position: Q1 2026 in Review
Susquehanna International Group increased its Protalix BioTherapeutics (PLX) stake by 27% in Q1 2026, buying an estimated $26.2K and bringing the position to 49,085 shares worth $107K. The position accounts for ﹤0.01% of the portfolio, ranked #12301.
Susquehanna International Group first reported a position in PLX in Q3 2013 and has held it in 37 quarters since. The position peaked at $2.2M in Q1 2025. 99 funds tracked by Wall St. Rank hold PLX as of Q1 2026.
- Susquehanna International Group held 49,085 shares of Protalix BioTherapeutics worth $107K as of Q1 2026.
- Susquehanna International Group bought 10,567 Protalix BioTherapeutics shares in Q1 2026, an estimated $26.2K.
- Protalix BioTherapeutics made up ﹤0.01% of Susquehanna International Group's portfolio in Q1 2026, its #12301 holding.
- Susquehanna International Group first reported a position in Protalix BioTherapeutics in Q3 2013 and has held it in 37 quarters since.
- Susquehanna International Group's Protalix BioTherapeutics position peaked at $2.2M in Q1 2025.
- 99 funds tracked by Wall St. Rank held Protalix BioTherapeutics as of Q1 2026.
Based on Susquehanna International Group's 13F filing for Q1 2026, filed 15 May 2026.